Viamet to Present at the 3rd Annual Dermatology Summit
One of Eight Companies Selected to Present at Entrepreneurial Showcase
Viamet Pharmaceuticals, Inc. today announced that the company will present at the 3rd Annual Dermatology Summit. The conference will take place on January 10, 2016 from 9:30 am to 7:00 pm PST at the Palace Hotel in San Francisco, CA.
The Viamet presentation will highlight VT-1161, a novel, highly potent and selective, oral inhibitor of fungal CYP51, a well-validated antifungal target. During the presentation, Amir Tavakkol, Ph.D., Viamet Chief Development Officer, will provide an update on the company’s ongoing RENOVATE Phase 2b clinical trial of VT-1161 for the oral treatment of toenail onychomycosis.